-+ 0.00%
-+ 0.00%
-+ 0.00%

Dermata Therapeutics To Present Phase 3 STAR-1 XYNGARI Abstract Highlighting Data In Moderate-To-Severe Acne At EADV Congress 2025

Benzinga·09/17/2025 06:14:53
Listen to the news

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -